Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Alzheimer’s May Not Originate in the Brain

By Kenny Walter | November 1, 2017

The long assumption that Alzheimer’s disease originates in the brain may not be true after all— as new findings indicate the disease could be triggered by breakdowns elsewhere in the body.

Researchers from the University of British Columbia (UBC) believe that the new discovery could lead to new drug therapies that may be able to stop or slow the disease down without acting directly on the brain, an often complex, sensitive and hard-to-reach target.

The researchers were able to demonstrate the cancer-like mobility of the disease with a technique called parabiosis—where they surgically attached two specimens together so they share the same blood supply for several months.

The researchers modified normal mice, which do not naturally develop Alzheimer’s, to carry a mutant human gene that produces high levels of a protein called amyloid-beta that ultimately forms clumps or plaques that smother brain cells in humans.

Amyloid-beta is produced in blood platelets, blood vessels and muscles and its precursor protein is found in several other organs.

However, until the current experiment it was unclear if the protein from outside the brain could contribute to Alzheimer’s disease.

“The blood-brain barrier weakens as we age,” UBC Psychiatry Professor Dr. Weihong Song, Ph.D., said in a statement. “That might allow more amyloid beta to infiltrate the brain, supplementing what is produced by the brain itself and accelerating the deterioration.”

The mice that had been joined to the genetically modified partners for a year ended of contracting Alzheimer’s disease. The amyloid-beta traveled from the genetically-modified mice to the brains of their normal partners, where it accumulated and began to inflict damage.

Along with developing plaques, the mice also developed a pathology similar to tangles—twisted protein strands that form inside brain cells, disrupting their function and eventually killing them from the inside-out.

The mice also developed Alzheimer’s-like damage including brain cell degeneration, inflammation and microbleeds, as well as the impairment of the ability to transmit electrical signals involved in learning and memory—even in mice that had been joined for just four months.

According to Song, a potential drug could bind to amyloid-beta throughout the body, tagging it biochemically in a way that the liver or kidneys could clear it.

“Alzheimer’s disease is clearly a disease of the brain but we need to pay attention to the whole body to understand where it comes from and how to stop it,” he said.

The study was published in Molecular Psychiatry

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE